United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 10mmol/500ml) / glucose 4% / sodium chloride 0.18% infusion 500ml bags (baxter healthcare ltd - potassium chloride; glucose anhydrous; sodium chloride - infusion - 1.5mg/1ml ; 40mg/1ml ; 1.8mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 27mmol/10ml) solution for infusion 10ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 200mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 40mmol/1litre) / glucose 4% / sodium chloride 0.18% infusion 1litre viaflo bags (baxter healthcare ltd - glucose anhydrous; potassium chloride; sodium chloride - infusion - 40mg/1ml ; 3mg/1ml ; 1.8mg/1ml

Singapore - English - HSA (Health Sciences Authority)

orient europharma pte ltd - vinflunine ditartrate 34.175 mg/ml eqv vinflunine - infusion, solution concentrate - 25mg/ml - vinflunine ditartrate 34.175 mg/ml eqv vinflunine 25mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: octanoate; sodium; water for injections - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium; octanoate - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 8.6 g/l; calcium chloride dihydrate, quantity: 330 mg/l; potassium chloride, quantity: 300 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - for restoring the loss of water and electrolytes as required by the clinical condition of the patient.

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 25 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 100 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - injection, concentrated - excipient ingredients: glacial acetic acid; sodium chloride; water for injections; sodium acetate trihydrate - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.